COVID-19 Vaccine Sponsors Want US FDA To Find Alternatives For Control-Arm Data After First EUA
US FDA must rethink guidance on maintaining placebo-control in COVID-19 trials after any vaccine gets an EUA, companies say, arguing current proposal may not be ethical or feasible. Disease organizations who agree with the hurdles to preserving placebo-control maintain this is a reason why any EUA must meet a very high standard.
You may also be interested in...
Omega Launches Aerium With ‘Substantial’ Cash, Two Antibodies Against SARS-CoV-2
Its antibodies will enter the clinic soon, but pandemic- and epidemic-focused Aerium plans to raise series B funds to take the assets all the way to an EUA in the US and pursue antiviral drug development.
Placebo Unblinding Process For Pfizer’s COVID Vaccine No Detriment To US FDA Safety Analysis
Despite initial concerns among FDA staff and its advisory committee about unblinding the Comirnaty pivotal trial after emergency authorization, agency’s review of the first COVID vaccine to receive full licensure suggests its safety conclusions were not adversely affected.
US COVID-19 Advisors Vexed By Vaccine Post-EUA Placebo Controls, But Agree On Need
FDA indicates it expects sponsors and other government agencies to come up with ways to fulfill its request for placebo-controlled studies post-emergency use authorization of COVID-19 vaccines, but neither it nor vaccines advisory committee see a clear way to do this.